All financings
COMPANY TRANSACTIONS

Hoth Therapeutics, Inc.

HOTHNasdaqBiotechnology

Deal details

1 transaction in the database

TRANSACTION REPORT · SEC DISCLOSURES
Gross proceeds$2.0M
Offering price$0.70
Discount to prior close16.7%
Warrant coverage100%
Placement agent / underwriterH.C. Wainwright & Co.

Transaction overview

01

Hoth Therapeutics, Inc. completed a $2.0M registered direct at $0.70 per share. H.C. Wainwright & Co. acted as exclusive placement agent for the financing.

Financing type
Registered Direct
Announcement date
Apr 1, 2026
Pricing date
—
Closing date
Apr 2, 2026
Filing date
Apr 2, 2026
Status
Closed
Market cap before announcement
$13.3M
Prior closing price
$0.8403
Raise as % of market cap
15.1%

Market data · FMP

Historical market cap
$13,270,300
Market date
Mar 31, 2026
Closing price
$0.8403
Latest reported shares outstanding
13,259,027
Latest reported float shares
12,705,463
Share-data date
Sep 5, 2026

Market cap and closing price are from FMP for the date shown. Shares are FMP’s latest available snapshot, dated separately. Updated Sep 30, 2026.

Financial Modeling Prep ↗

Financing terms

02

Equity

Common shares issued
2,857,144
Price per share
$0.70
Pre-funded warrants
—
Pre-financing shares disclosed in filing
16,270,499
Shares outstanding after financing
—

Investor warrants

Warrant shares
2,857,144
Cash exercise price
$0.85
Term
Five and one-half years from issuance; exercisable six months after issuance.
Initial exercisability
—
Beneficial ownership limits
4.99%; may increase to 9.99% with at least 61 days’ prior notice.

Placement agent warrants

Warrant shares
142,857
Cash exercise price
$0.875
Term
Five years from commencement of sales; immediately exercisable upon issuance.
Initial exercisability
—
Beneficial ownership limits
—

Compensation warrants are excluded from investor warrant coverage.

Fees & transaction economics

03
Placement agent / underwriting fee
7%
Agent fee amount
$140,000.06
Management fee
1%
Other offering expenses (estimated)
—
Net proceeds (estimated)
—
Net proceeds as % of gross
—

Fee amounts reflect disclosed inputs. Unknown expense components are not assumed to be zero.

In addition, the Company agreed to pay the Placement Agent $20,000 for non-accountable expenses and $35,000 for fees and expenses of legal counsel and other out-of-pocket expenses and $15,950 for clearing fees.

Transaction participants

04
Investor names: —

Source documents

05

SEC filings, exhibits and attributed market data. The report separates disclosed facts, calculated metrics, and unknown terms.

424B5 · Hoth Therapeutics, Inc.SEC filing · Apr 2, 2026
Open source ↗
8-K · Hoth Therapeutics, Inc.SEC filing · Apr 2, 2026
Open source ↗
EX-10.1 · Hoth Therapeutics, Inc.SEC filing · Apr 2, 2026
Open source ↗
EX-99.1 · Hoth Therapeutics, Inc.SEC filing · Apr 2, 2026
Open source ↗
EX-99.2 · Hoth Therapeutics, Inc.SEC filing · Apr 2, 2026
Open source ↗
SEC deal terms · FMP market data where available · Initial research sample, not complete market coverage. AI-assisted source review; original evidence is available in each report. Names and tickers reflect the transaction date. A dash (—) means the value is unavailable.